Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil falls as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
March 19, 2019 4:02 PM EDTVICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.
2018 and Recent Highlights
Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims which have the potential to cover voclosporins method of use and dosing protocol for lupus nephritis (LN) until December 2037. Phase 2a Dry Eye Study results released in January 2019 demonstrating statistically superior efficacy of... More